Updated on:2026-10-19

Overall H1 Development Overview.Time moves forward and so does our effort.In H1 2026, Nanjing Zhihe upheld its mission of clinical-demand oriented, innovation-first, customer-centered.

Updated on:2026-10-19

On the morning of June 4, 2026, a Zhihe delegation led by Chairman Dr. Zhang Zhefeng, Vice Chair Hou Wen, Chief AI Scientist Dr. Dai Yujie, Head of Molecular Design Research Institute Dr. Fu Haijian, AI Center backbone members, and the IT head visited Qilin Science and Technology Innovation Park.

Updated on:2026-10-19

Amid the global GLP-1 receptor-agonist boom, oral peptide technology is trying to crack the daily injection compliance problem.But another path — long-acting injectables (LAI) — is reshaping chronic-disease care with a one shot, months of relief model.

Updated on:2026-10-19

Peptides face multiple natural barriers: large molecular weight, protease sensitivity, and very low intestinal permeability.

Updated on:2026-10-19

On April 1, 2026, the oral small-molecule GLP-1 Orforglipron was approved, ushering the GLP-1 space into the oral era.Novo Nordisk\\\'s oral product was approved earlier; more than fifteen Chinese companies are advancing clinical programs.

Updated on:2026-10-19

Small nucleic acid therapeutics are the third major drug modality after small molecules and antibodies, with over 300 pipelines in development globally in 2026.

Updated on:2026-10-19

Data sources: PharmCube, PharmaGoGlobal, Sina Finance, NMPA, and other public sources | Compiled by Nanjing Zhihe

Updated on:2026-10-19

An in-situ forming gel is a delivery system that spontaneously forms a gel network at the administration site.Phase transition is triggered by temperature, pH, ionic cues, or enzymatic reactions.

Updated on:2026-10-19

In 2025, the number of ADCs in clinical development worldwide surpassed 200, spanning more than 50 targets.Yet the three traditional targets — HER2, TROP2, and Claudin18.2 — have fallen into homogeneous competition.

Updated on:2026-10-19

Technology breakthroughs: Chinese players are at the global frontier in ADCs, bispecifics, and T-cell engagers.Strategic window: Global innovative-drug financing is rebounding; CXO sentiment is recovering.

Updated on:2026-09-12

Nanjing Zhihe made a brilliant appearance at Booth 3E-A09 and looks forward to seeing you again! Nanjing Zhihe Pharmaceutical Technology Co., Ltd. — Exhibition Recap

Updated on:2025-05-27

Updated on:2025-05-20

Updated on:2025-04-21

Updated on:2025-04-07